Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 7/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.36 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662827 | 0.86 | NTRK1 (0.40) | BACE1MAP4K1NTRK1F10HTR1A | |
| SCHEMBL670900 | 0.79 | MAP4K1 (0.50) | BACE1MAP4K1NTRK1F10PTGS2 | |
| SCHEMBL21753351 | 0.78 | F10 (0.53) | F10PTGS2 | |
| SCHEMBL1662765 | 0.76 | GPR183 (0.45) | NTRK1 | |
| SCHEMBL672446 | 0.74 | PER2 (0.36) | BACE1MAP4K1NTRK1F10HTR1A | |
| SCHEMBL2940366 | 0.74 | MAP4K1 (0.50) | MAP4K1NTRK1F10PTGS2PIK3CD | |
| SCHEMBL18099235 | 0.73 | F10 (0.43) | MAP4K1NTRK1F10PTGS2PIK3CD | |
| SCHEMBL18630668 | 0.72 | F10 (0.54) | F10HTR1APTGS2 | |
| SCHEMBL673330 | 0.71 | NTRK1 (0.42) | MAP4K1NTRK1F10PTGS2PIK3CD | |
| SCHEMBL21822109 | 0.69 | PTGS2 (0.41) | MAP4K1F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| EP-2491039-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | Cellzome Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011048082-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | BACE1 2780/4885MAP4K1 246/4885NTRK1 4772/4885 |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | BACE1 3082/4885MAP4K1 177/4885NTRK1 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.